⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCAB News
BioAtla, Inc. Common Stock
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
globenewswire.com
BCAB
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
globenewswire.com
BCAB
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
globenewswire.com
BCAB
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
globenewswire.com
BCAB
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
globenewswire.com
BCAB